Sign in
CompletedNo phase

Smoking Reduction In Gravid Substance Use Disorders

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Status
Completed
People taking part
74 people enrolled
Started
15 Feb 2021
Ended
1 Dec 2023
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels
Record updated
5 August 2024

Who can take part

Age
16 years to 45 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age 16-45
  • Singleton gestation
  • Gestational age at enrollment <24 weeks
  • Substance use disorder defined as modified National Institute on Drug Abuse ASSIST ≥4
  • Cigarette smoker using ≥10 cigarettes/day interested in quitting

Who cannot take part

  • Known or suspected fetal growth restriction at enrollment
  • Known fetal anomaly, aneuploidy, or demise
  • Not interested in smoking cessation or reduction during pregnancy
  • E-cigarette use

Where in United States

  • University of AlabamaBirmingham, United States

About the trial

What the trial wants to find out

The aim of this study is to encourage smoking cessation in women with substance use disorders by providing knowledge of expired carbon monoxide. We hypothesize that women who are provided knowledge of their expired carbon monoxide and the associated percent fetal carboxyhemoglobin will have a greater success at quitting smoking during pregnancy than women who are not provided this information.

Read full original descriptionShow less

A secondary aim of the study is to correlate expired carbon monoxide throughout pregnancy with infant birth weight.

The 2 groups in the trial

  • Treatment GroupTreatment being tested

    1. The patient will exhaled into the Smokerlyzer® device will at each visit 2. Exhaled carbon monoxide and fetal carboxyhemoglobin levels will be disclosed to the patient 3. Risks of adverse perinatal outcomes related to maternal carboxyhemoglobin and fetal carboxyhemoglobin level will be provided.

    Treatment: knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels

  • Control GroupNo study treatment, for comparison

    1. The patient will exhale into the Smokerlyzer® device at each visit. 2. Exhaled carbon monoxide and fetal carboxyhemoglobin level will NOT be disclosed to the patient 3. No risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin levels will be provided

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Smoking Reduction In Gravid Women With Substance Use Disorders (SIGS): A Randomized Controlled Trial
Record updated
5 August 2024